These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 21385649)
41. Early migration of an Amplatzer muscular ventricular septal defect occluder device causing severe tricuspid valve obstruction. Panduranga P; Al-Farqani A; Al-Maskari S J Cardiovasc Med (Hagerstown); 2012 May; 13(5):336-7. PubMed ID: 22089813 [TBL] [Abstract][Full Text] [Related]
42. Transcatheter closure of recurrent postmyocardial infarction ventricular septal defect facilitated by percutaneous left ventricle access. Love BA; Nielsen J; Chinitz J; Filsoufi F Semin Thorac Cardiovasc Surg; 2010; 22(3):259-61. PubMed ID: 21167463 [TBL] [Abstract][Full Text] [Related]
43. Residual VSD closure with an ADO II device in an infant. Ramakrishnan S; Saxena A; Choudhary SK Congenit Heart Dis; 2011; 6(1):60-3. PubMed ID: 21269415 [TBL] [Abstract][Full Text] [Related]
44. Transcatheter closure of a posttraumatic ventricular septal defect with an Amplatzer occluder device. Bauriedel G; Redel DA; Schmitz C; Welz A; Schild HH; Lüderitz B Catheter Cardiovasc Interv; 2001 Aug; 53(4):508-12. PubMed ID: 11515002 [TBL] [Abstract][Full Text] [Related]
45. Evolution in the management of postinfarct ventricular septal defects from surgical to percutaneous approach: a single-center experience. Sathananthan J; Ruygrok P J Invasive Cardiol; 2013 Jul; 25(7):339-43. PubMed ID: 23813062 [TBL] [Abstract][Full Text] [Related]
46. Risk factors and outcomes of post-procedure heart blocks after transcatheter device closure of perimembranous ventricular septal defect. Yang R; Kong XQ; Sheng YH; Zhou L; Xu D; Yong YH; Sun W; Zhang H; Cao KJ JACC Cardiovasc Interv; 2012 Apr; 5(4):422-7. PubMed ID: 22516400 [TBL] [Abstract][Full Text] [Related]
47. A case of late-onset sustained ventricular tachycardia following deployment of Amplatzer-type perimembranous VSD occluder. Zhou K; Hua Y; Qiao L Catheter Cardiovasc Interv; 2014 Feb; 83(2):256-60. PubMed ID: 22927019 [TBL] [Abstract][Full Text] [Related]
48. Development and preclinical evaluation of a biodegradable ventricular septal defect occluder. Huang XM; Zhu YF; Cao J; Hu JQ; Bai Y; Jiang HB; Li ZF; Chen Y; Wang W; Qin YW Catheter Cardiovasc Interv; 2013 Feb; 81(2):324-30. PubMed ID: 22888016 [TBL] [Abstract][Full Text] [Related]
49. Few comments regarding transcatheter closure of congenital perimembranous and muscular ventricular septal defects. Bialkowski J; Szkutnik M; Kusa J; Fiszer R Int J Cardiol; 2010 Nov; 145(1):69; author reply 70. PubMed ID: 19481281 [TBL] [Abstract][Full Text] [Related]
50. Percutaneous closure of postinfarct muscular ventricular septal defects: a multicenter study in China. Xu XD; Liu SX; Liu X; Chen Y; Li L; Qu BM; Wu ZY; Zhang DF; Zhao XX; Qin YW J Cardiol; 2014 Oct; 64(4):285-9. PubMed ID: 24674748 [TBL] [Abstract][Full Text] [Related]
51. Transcatheter closure of perimembranous ventricular septal defect with immediate follow-up. Durongpisitkul K; Soongswang J; Laohaprasitiporn D; Nana A; Nutakul T J Med Assoc Thai; 2003 Oct; 86(10):911-7. PubMed ID: 14650702 [TBL] [Abstract][Full Text] [Related]
52. A novel method of hybrid intraoperative catheter-based closure of ventricular septal defects using the Amplatzer® PDA occluder. Neukamm C; Bjørnstad PG; Fischer G; Smevik B; Lindberg HL Catheter Cardiovasc Interv; 2011 Mar; 77(4):557-63. PubMed ID: 20518011 [TBL] [Abstract][Full Text] [Related]